dievini Hopp BioTech holding GmbH & Co. KG
  • Home
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • Unternehmensmeldungen
  • Impressum
  • Datenschutz
  • English
dievini Hopp BioTech holding GmbH & Co. KG
  • Home
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • Unternehmensmeldungen
  • Impressum
  • Datenschutz
  • English
  • Home
  • News 2021

13.04.2021: Novaliq GmbH

BAUSCH + LOMB ANNOUNCES STATISTICALLY SIGNIFICANT TOPLINE RESULTS FROM THE FIRST PHASE 3 TRIAL OF NOV03 (PERFLUOROHEXYLOCTANE) IN DRY EYE DISEASE ASSOCIATED WITH MEIBOMIAN GLAND DYSFUNCTION

All Primary and Secondary Endpoints Were Achieved

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”), and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced statistically significant topline data from the first Phase 3 trial (GOBI trial) evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD).

Den gesamten Artikel lesen Sie bitte hier

News 2021

08.12.2020: Novaliq GmbH

Novaliq Announces First Patient Randomized in the Phase 3 trial ESSENCE-2 of CyclASol® Topical Ophthalmic Solution for the Treatment of Dry Eye Disease

  • ESSENCE-2 is the second registration trial to complete the clinical development of CyclASol® as agreed with U.S. Food and Drug Administration (FDA)
  • Designed to replicate efficacy demonstrated in previous phase 2/3 ESSENCE-1 trial
  • Topline data expected in 2nd half 2021

Novaliq, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced that it has initiated the randomization of patients in its phase 3 clinical trial ESSENCE-2 that is designed to replicate efficacy results of the previous phase 2/3 ESSENCE-1 trial.

Den gesamten Artikel lesen Sie bitte hier

News 2020

23.07.2020: Novaliq GmbH

Novaliq Provides Development Update on CyclASol® Topical Ophthalmic Solution for the Treatment of Dry Eye Disease

  • CyclASol® has the potential to change the way eye care practitioners treat patients with dry eye disease
  • EyeSol®, the unique water-free technology, unfolds the full potential of cyclosporine A on the ocular surface with an unprecedented tolerability profile
  • Novaliq agreed with the U.S. Food and Drug Administration (FDA) that the second registrational trial, ESSENCE-2, is expected to complete the clinical development of CyclASol®
  • ESSENCE-2 is a multicenter, randomized, double-masked, vehicle-controlled clinical trial expected to start in the second half of 2020

Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, today provided a development update on its investigational water-free and preservative-free drug CyclASol®.

CyclASol® is a topical anti-inflammatory and immunomodulating ophthalmic solution, containing 0.1% cyclosporine A in EyeSol®, developed for the treatment of dry eye disease. The unique water-free formulation increases residual time on the ocular surface and enables a high bio-availability in the target tissues to unfold the full potential of cyclosporine A. The multi-dose, preservative-free, smaller and more physiologic droplet size profile provides unique clinical benefits and outstanding tolerability. Notably, the improvement in visual function associated with a clinically significant reduction of corneal staining, as shown in the recent Phase 2/3 clinical ESSENCE-1 trial, will differentiate CyclASol® from existing therapies.

Den gesamten Artikel lesen Sie bitte hier

News 2020

20.12.2019: Novaliq GmbH

BAUSCH HEALTH LICENSES NOVALIQ’S NOV03 INVESTIGATIONAL TREATMENT FOR DRY EYE DISEASE ASSOCIATED WITH MEIBOMIAN GLAND DYSFUNCTION

Bausch Health Companies Inc. (“Bausch Health”) and Bausch + Lomb, its leading global eye health business, and Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced today that Bausch Health has acquired an exclusive license for the commercialization and development in the United States and Canada of the investigational treatment NOV03 (perfluorohexyloctane), a first-in-class investigational drug with a novel mechanism of action to treat Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD).

Den gesamten Artikel lesen Sie bitte hier
News 2019

08.11.2019: Novaliq GmbH

Novaliq and Jiangsu Hengrui Medicine announce a strategic collaboration in ophthalmology for the EyeSol®-based investigational products NOV03 and CyclASol® in China

  • Jiangsu Hengrui Medicine secures exclusive rights to develop, manufacture, and commercialize NOV03 and CyclASol® in China.
  • NOV03 (perfluorohexyloctane) is a first-in-class investigational drug with a novel mode of action to treat Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD).
  • CyclASol® (0.1% cyclosporine A in EyeSol®) is an anti-inflammatory and immunomodulating investigational drug developed for the treatment of aqueous deficient DED.
  • Novaliq is eligible to receive upfront and milestone payments of up to 165 million plus royalties.

Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, and Jiangsu Hengrui Medicine Co., Ltd. (SSE: 600276), a fully integrated biopharmaceutical company based in China, announce today the closing of an exclusive license agreement to develop, manufacture, and commercialize the innovative, water-free drugs NOV03 and CyclASol® for the treatment of dry eye disease in People’s Republic of China (including mainland China, Hong Kong, Macau and Taiwan).

Den gesamten Artikel lesen Sie bitte hier
News 2019

10.09.2019: Novaliq GmbH

NOVALIQ RECOGNISED IN CLINICAL TRIAL OF THE YEAR FINALIST ROSTER AT EUROPEAN LIFESTARS AWARDS

Celebrating success across life sciences

Novaliq is pleased to announce that it has been recognised in the finalist roster of the Clinical Trial of the Year at the 2019 Lifestars AwardsTM.

Lifestars is a celebration of the success stories, innovations, transformational deals and the people, teams and organisations that play such a critical role in the advancement of the industry over the last 12 months across Europe and the US.

Den gesamten Artikel lesen Sie bitte hier
News 2019

25.04.2019: Novaliq GmbH

NOVALIQ AND BLP MANAGEMENT GROUP ESTABLISHED NEW COMPANY, BETALIQ INC., TO LEVERAGE EYESOL TECHNOLOGY TO TREAT GLAUCOMA

  • Betaliq is developing ophthalmic ß-blockers for the treatment of glaucoma using Novaliq’s waterfree EyeSol® technology
  • Betaliq successfully collected proceeds in a Series A round

Novaliq GmbH, a specialty pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol® and BLP Management group today announce the formation and funding of Betaliq Inc., a new company located in Tampa, Florida.

Den gesamten Artikel lesen Sie bitte hier
News 2019

26.02.2019: Novaliq GmbH

Novaliq named Finalist in “Clinical Trial Result of the Year” category of the Clinical & Research Excellence Awards CARE 2019


Novaliq, the pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on the water-free EyeSol® technology, has been named a finalist in “Clinical Trial Result of the Year” category of the CARE Awards, which recognizes outstanding work across the global clinical research enterprise

Den gesamten Artikel lesen Sie bitte hier

News 2019

24.10.2018: Novaliq GmbH

NOVALIQ ANNOUNCES POSITIVE TOPLINE RESULTS FOR ITS SEECASE PHASE 2 RIAL OF NOV03 FOR THE TREATMENT OF PATIENTS WITH DRY EYE DISEASE


Novaliq, a specialty pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology for ophthalmology, today announces positive topline results for its EECASE phase 2 clinical trial of NOV03 for the treatment of dry eye disease (DED) in ore than 300 patients.

Den gesamten Artikel lesen Sie bitte hier

News 2018

18.10.2018: Novaliq GmbH

NOVALIQ ANNOUNCES POSITIVE TOPLINE RESULTS FOR ITS CYCLASOL® PHASE 2b/3 ESSENCE TRIAL IN PATIENTS WITH DRY EYE DISEASE


Novaliq, a specialty pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology for ophthalmology, today announces positive topline results from ESSENCE, its first pivotal clinical trial of CyclASol® 0.1% for the treatment of dry eye disease (DED).

Den gesamten Artikel lesen Sie bitte hier

News 2018
Older Entries
  • News 2021
  • News 2020
  • News 2019
  • News 2018
  • Unternehmen
    • AC Immune SA
    • Apogenix AG
    • Cassiopea SpA
    • Cosmo Pharmaceuticals NV
    • CureVac AG
    • Heidelberg Pharma AG
    • Immatics Biotechnologies GmbH
    • Joimax GmbH
    • Molecular Health GmbH
    • Novaliq GmbH

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz